Atara Biotherapeutics Inc  

(Public, NASDAQ:ATRA)    
Find more results for John T. Isaacs, Ph.D.�

Officers and directors

Isaac E. Ciechanover M.D.
President, Chief Executive Officer, Director
John F. McGrath Jr.
Chief Financial Officer
Gad Soffer
Chief Operating Officer
Mitchall G Clark
Chief Regulatory and Quality Assurance Officer
Christopher M. Haqq M.D., Ph.D.
Chief Medical Officer
Carol G. Gallagher
Lead Independent Director
Matthew K. Fust
Independent Director
Joel S. Marcus J.D., CPA.
Independent Director
Beth C. Seidenberg M.D.
Independent Director


3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States - Map
+1-415-2872410 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The Company�s product candidates are biologics targeting myostatin and activin, members of the Transforming Growth Factor-Beta (TGF-B), protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The Company�s lead product candidate, PINTA 745, is in a Phase II clinical trial for protein-energy wasting, a condition affecting many end-stage renal disease patients. Its second product candidate is STM 434. The Company has five additional molecules in preclinical development.

Related companies

* Delayed by up to 20 minutes -  Disclaimer